Hillary White
Registered Nurse · Oklahoma City, OKNPI 1992127310
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 28.7% of the total. Reporting peaked in 2021 at $905 and has fallen 78.1% since, to $198 in 2025. Among registered nurse clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$792
- AstraZeneca$351
- Novo Nordisk$205
- Lilly USA, LLC$155
- Idorsia Pharmaceuticals US Inc$137
- Collegium Pharmaceutical, Inc.$133
- plus $984 from 23 others
What the payments were for
- Food & beverage$2,756100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $792 |
| AstraZeneca | 18 | $351 |
| Novo Nordisk | 13 | $205 |
| Lilly USA, LLC | 11 | $155 |
| Idorsia Pharmaceuticals US Inc | 8 | $137 |
| Collegium Pharmaceutical, Inc. | 13 | $133 |
| Amgen(2 entities) | 5 | $84 |
| Antares Pharma, Inc. | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Boehringer Ingelheim | 4 | $69 |
| Corium, LLC | 3 | $66 |
| Abbott | 3 | $65 |
| GSK | 4 | $64 |
| Halozyme Inc | 2 | $57 |
| Pfizer | 3 | $55 |
| Eisai Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Exact Sciences | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Edwards Lifesciences | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $26 |
| Organogenesis Inc. | 1 | $25 |
| Vyera Pharmaceuticals, LLC | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Avion Pharmaceuticals | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $14 |
How this compares
$2,756 in reported general payments places this provider in the 90th percentile of 23 registered nurse providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $54,312 |
| OzempicSemaglutide | 17 | $25,790 |
| LinzessLinaclotide | 16 | $12,818 |
| MyrbetriqMirabegron | 19 | $8,338 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,748 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,622 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $1,785 |
| Sumatriptan Succinate | 38 | $1,478 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,178 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,028 |
| Aripiprazole | 17 | $681 |
| Levothyroxine Sodium | 68 | $608 |
| Metformin Hcl | 53 | $532 |
| Gabapentin | 47 | $529 |
| Omeprazole | 32 | $516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $155 | $54,31241 claims |
| Novo NordiskOzempic | $205 | $25,79017 claims |
| AbbVieLinzess | $792 | $12,81816 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $8,33819 claims |
| GSKIncruse Ellipta | $64 | $4,74813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 registered nurse providers in Oklahoma.
Other registered nurse in Oklahoma City
- Terrie TerrellOklahoma City$6K
- Robin JohnsonOklahoma City$1K
- Arjun PillaiOklahoma City$81
- Joshy ShabuOklahoma City$30
- Samuel NjorogeOklahoma City$29
- Melissa CaseOklahoma City$18
- Wanda Meler-PoteetOklahoma City$18
- Patricia StevensonSkiatook$726K
- Leslie JeffriesMcAlester$941
- Larmeta GettesNorman$362
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.